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Abstract 
Human Beta Defensins (hBD-s) are a class of antimicrobial peptides (AMPs) 
that play an important role both in innate and adaptive immunity. In fact, they 
directly kill bacteria (Gram+, -), viruses and fungi and exert chemotaxis against 
dendritic cells, lymphocytes and monocytes. Thanks to their antimicrobial and 
chemotactic activity, hBD-s represent a good target to develop new 
therapeutic molecules (Scudiero et al. 2010).  
Previously, Scudiero et al. synthesized the wild type hBD-1, hBD-3 and 
designed eight analogs selecting the sequences of hBD-1 and -3 that are 
crucial tracts for their activity. They demonstrated that the C-terminal domain 
of hBD-3 and the internal portion of hBD-1 are necessary for the antibacterial, 
antiviral and chemotactic activity; they demonstrated that 1C and 3N are the 
only two analogs with higher activity respect to the wild type confirming that 
this is a potent strategy to develop new pharmacological molecules. 
In the present study, we tested the possibility to find a new defensin analog 
with enhanced antimicrobial properties. We designed a new peptide, 3NI, 
with the following features: (a) shorter total sequence in order to provide 
greater stability and ability to penetrate bacteria and viruses; (b) presence of 
the C-terminus portion of hBD-3 selected for the antimicrobial activity; (c) 
presence of inner portion of hBD-1 selected for the chemotactic activity. At 
this aim, we used 3NI to perform antibacterial tests on E.coli, P. aeruginosa, E. 
faecalis and demonstrated that it suppresses bacterial growth already at a 
concentration of 12.5 µM. We also tested the antiviral activity on herpes 
simplex virus type 1 and found that 3NI suppresses the infectivity at a 
concentration of 50 µM. Therefore, our results indicate that 3NI analog 
represents a new attractive target for therapeutic approaches. 
In addition, we investigated two others pharmacological properties of these 
peptides: the stability in human serum and the potential cytotoxic effects 
using human cell lines. We demonstrated that hBD-3, used as a reference, is a 
peptide with pronounced stability; in fact it resulted not degraded after 1 
hour of serum incubation and with a degradation rate of 45% after 24 hours.  
Successively, to evaluate the cytotoxic effects of hBD-1, hBD-3 and 1C, 3N and 
3NI analogs, we tested cell viability, apoptosis and DNA damage using three 
human epithelial cell lines: lung carcinoma (A549), colon carcinoma (CaCo-2) 
and pancreas adenocarcinoma (Capan-1). In all cell lines, we demonstrated 
that the peptides cause 30% reduction of cell viability and 20% of apoptosis 
only after 72 hours treatment. In addition, we demonstrated that the 
peptides do not induce DNA damage. 
Finally, in order to investigate whether defensins interact with plasma 
membranes and penetrate into human epithelial cell lines, we labeled our 
peptides with NBD fluorochrome and performed confocal microscopy 
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experiments. We observed that peptides bind to plasma membranes and 
penetrate into A549 and CaCo-2 cells through active mechanisms involving 
early endosomes. We observed that they are partially digested through 
lysosomes.  
Altogether our results confirm that the beta defensins analogs are attractive 
factors to develop new antimicrobial molecules with therapeutic applicability 
for the treatment of infectious diseases. In fact, 1C, 3N and 3NI are analogs 
that show an increased antimicrobial activity compared to wild type 
defensins, do not exert relevant cytotoxic effects and have pronounced 
stability in human serum.  
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1 Introduction 
1.1 Innate and adaptive immune system  
 
Although microorganisms surround and vastly outnumber us, very few 
succeed in causing illness. To cause infections, pathogens must entire our 
organism and counteract the complex system of tissues, cells and molecules 
responsible for the defence of our body, collectively known as immune 
system (Reddy et al. 2004; Lehrer et al 2004).  
The immune system is a network of tissues, organs, cells, and chemicals that 
protects the body against infections. In humans, two types of immunity are 
known: innate and adaptive. Innate immunity, given to us by birth, provides 
the first barrier against microorganisms. Adaptive immunity, instead, refers to 
antigen-specific defense mechanisms that take several days to become 
protective; it is acquired later in life, such as after an immunization or 
successfully fighting off an infection. The two immune systems tightly 
cooperate (Iwasaki et al. 2010): in fact, the innate immune system can initiate 
adaptive immune responses (Medzhitov et al. 2000).  
The innate immune system is commonly considered to be a mechanism of 
immunity primitive and highly conserved during the evolution. It is activated 
immediately (few minutes) after infection and rapidly controls replication of 
the infecting pathogen. Its activation is based on the recognition of molecules 
considered non-self through receptors, called pattern-recognition receptors 
(PRRs). PRRs are expressed on several immune cells including macrophages, 
dendritic cells and lymphocytes B and are able to recognize non-self 
molecules, antigens. The strategy of the innate immune response is to identify 
some highly conserved structures associated to pathogens as 
lipopolysaccharide, peptidoglican and double strand RNA, collectively called 
pathogen-associated molecular patterns (PAMPs). PAMPs are existing 
structures in large groups of microbes (Medzhitov et al. 1997; Janeway et al. 
2002). In this way, the innate immune activity mechanism is direct against 
whatever bacteria, fungi or viruses. 
The innate immune system displays three types of barriers: anatomical, 
cellular and humoral. The first includes skin, internal and external epithelial 
layers which act as physical barriers to invasion. The cellular barrier is 
activated after the invasion of pathogens. The main cellular components are 
macrophages, neutrophils, lymphocytes etc. that, after activation, secrete 
cytokines and chemokines to control host replication. The humoral barrier is 
constituted by peptides and small proteins with antimicrobial activity, 
collectively called antimicrobial peptides (AMPs). AMPs are secreted by 
epithelial cells after microbial stimuli.  
Altogether, these barriers participate to the defense of our organism 
(Medzhitov 2010; Dartois et al. 2005).  
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1.2 Antimicrobial Peptides   
 
AMPs are effector molecules of the innate immune system; they have a broad 
antimicrobial spectrum and lyse microbial cells by interaction with 
biomembranes. Besides their direct antimicrobial function, they have multiple 
roles as mediators of inflammation with impact on epithelial and 
inflammatory cells influencing diverse processes such as cell proliferation, 
immune induction, wound healing, cytokine release, chemotaxis and 
protease-antiprotease balance (Fig. 1). In this way, AMPs activate the 
adaptive immune system (Cederlund et al. 2011; Wiesner et al. 2010). To 
date, over 1500 peptides have been identified; they have antimicrobial 
activities from amoeba, plants, birds to humans. Usually, AMPs are classified 
based on secondary structural features, such as cathelicidins (linear α-helical 
peptides), defensins (β-strand peptides connected by disulfide bonds), and 
bactenecins (loop peptides) (Cederlund et al. 2011). The majority of these 
small peptides (fewer than 100 amino acids) share a common feature: the 
presence of a positive charge due to an excess of positively amino acids (i.e. 
arginine and lysine). The mechanism of action is based on their net positive 
charge. AMPs interact electrostatically with negative charges of microbial cell 
membranes (i.e. phospholipids), thereby increasing the membrane 
permeability and finally resulting in cell death (Bals et al. 2000; Brogden 
2005).  
In humans, two main categories of antimicrobial peptide play a key role in the 
defence of our organism: cathelicidins and defensins (Cederlund et al. 2011). 
They are both secreted by epithelial cells of many tissues as respiratory, 
urogenital and intestinal tracts.  
Actually, the antibiotic treatment of bacterial infections is still one of the 
mainstays of human medicine. It is thus a challenge to design new 
antimicrobial molecules with novel structure and mechanism of action. 
Antimicrobial peptides represent good templates for a new generation of 
antibiotics. AMPs qualify as prototypes of innovative drugs that may be used 
as antimicrobials and or reducing the inflammation. Several strategies have 
been used to design new molecules candidates for drug development, and to 
produce sufficient amounts for clinical studies. Many studies are now focused 
on the design and development of synthetic analogs of AMPs in order to find 
active molecules on viruses, fungi and bacteria (Reddy et al. 2004). 
8 
 
 
 
Fig. 1:  Antimicrobial peptides (AMPs) have two functions: they are able to direct kill 
microbes; they activate the adaptive immune system through chemotaxis toward several 
cells of immune system.   
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1.3 Defensins 
 
Defensins are a class of cationic AMPs arginine rich. They are small peptides 
highly conserved during the evolution from plants to humans (Lehrer 2004). 
They are secreted by immune cells as neutrophils, monocytes and epithelial 
cells of gastro-intestinal, pulmonary, urogenital epithelia. Moreover skin and 
placenta produce defensins (Ganz 2001; Selsted et al. 2005). They have 
antimicrobial activity against a broad spectrum of microorganisms, Gram-
positive, - negative, fungi and viruses (Hazlett et al. 2010) and exert 
chemotaxis toward dendritic cells, monocytes and lymphocytes. 
In humans three defensin subfamilies are known: α, β and θ defensins 
These peptides are produced as pre-pro-peptides of 94-95 amino acids that 
undergo two cleavage processes releasing the mature peptides of 29-34 
amino acids (Lehrer 2004).  
The mature defensins of the three subfamilies share some common features:    
- Short sequence: 18-50 amino acids (5-7 KDa) 
- Net cationic charge 
- Presence of 6 cystein residues  
- three intramolecular disulphide bonds due to the presence  of 6 
cysteins 
- Absence of post-traductional modifications  
They differ for: 
- The length of peptide segment between the 6 cysteines  
- The pairing of the cysteins that are connected by disulfide bonds 
- Tridimensional conformation. 
 
In humans, α and β defensins are the produced by two distinct genes evolved 
by a common ancestral gene; this process probably is probably due to the 
evolutionary response of the immune system to the continuous ecological and 
environmental changes (Selsted et al. 2005). The two genes are nearby and 
located on the chromosome 8.  
Moreover, θ defensins, identified and expressed only in primates, are cyclic 
peptides.  
The core of α and β defensin molecules consist of three beta strands arranged 
in anti-parallel sheets, which are constrained by the 3 intramolecular disulfide 
bridges (Lehrer 2004). In addition, in β defensin, but not in α class, the beta 
sheet is flanked by an alpha helical segment of variable length, corresponding 
to the N-terminal domain (Fig. 2).  
10 
 
The tridimensional conformation of both α and β defensins is of particular 
interest; in fact, it is possible to identify a C-terminal domain with a high 
cationic charge and an amphipatic domain at the N-terminus.  
This particular conformation and charges distribution are probably 
responsible for the antimicrobial activity of defensins (Selsted et al 2005).  
 
 
Fig. 2: Tridimensional representation of α, β and θ defensins.    
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1.4  Human Alpha Defensins 
 
α defensins are peptides of 29-35 amino acids. In humans, six α defensins 
have been isolated: HPN1, HPN3, HPN4, HD5, and HD6 HPN2; the latter is, 
however, a peptide truncated without proven activity. The genes encoding 
these six defensins are in the same region of the chromosome 8. 
The α defensins have been isolated from neutrophils and, more specifically, 
within the azurophilic granules in which HPN1-3 represent about the 50% of 
protein content while HNP4 is present at low concentrations (Patil et al. 
2004). Defensins HNP1-3 are also present in B and natural killer lymphocytes. 
The two defensins HD5-6 are defined as enteric defensins because they have 
been found in Paneth cells of the small intestine and in the epithelial cells of 
the female urogenital tract (endometrium, and fallopian tubes) (Cunliffe 
2003).  
From a functional point of view, the α defensins play a key role in oxygen-
dependent destruction of phagocytised microorganisms. 
 
 
1.5 Human Teta Defensins 
 
θ defensins are expressed in different species of monkeys and orangutans, 
but not in humans (Selsted 2004). The θ defensins are structurally different 
from α and β defensins: they are in fact cyclic peptides. Moreover, the gene 
encoding for θ defensins originates from the mutated gene of α defensins 
(Selsted 2004). The precursor of the θ defensins is a shorter paralogous of the 
α defensins because it is truncated by the insertion of a stop codon. The 
resulting mature peptide of 18 amino acids presents the classical 6 cysteines 
and 3 disulfide bridges that, making the structure very rigid, give rise the 
typical cyclic structure.  
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1.6 Human Beta Defensins 
 
Human β Defensins (hBD-s) are a family of small cationic peptides with a 
molecular weight ranged between 3-7 kDa (Pazgier et al. 2006). Three 
domains characterize the primary sequence: 
1. Six cysteins domain. These amino acids, highly conserved, are 
responsible for the formation of three disulfide bonds between 
residues 1-5, 2-4, 3-6. The disulphide bonds generate, in the 
tridimensional structure, three beta sheets and an alpha helix. If the 
presence of cysteins is fundamental for the antimicrobial activity is not 
yet clear (Chandrababu et al. 2009, Hoover et al. 2003, Kluver et al. 
2005, Wu et al. 2003).  
2. Cationic domain, constituted by several cationic amino acids 
(expecially arginine, lysine, histidine). In the tridimensional 
conformation, this domain is the most exposed on the surface because 
it is involved in the antimicrobial activity of the peptide interacting 
with microorganism surface. On the contrary of the six cysteines, these 
residues are not highly conserved to allow defensins to adapt to 
pathogens. 
3. Leader domain, highly hydrophobic. This domain in the tridimensional 
conformation of the peptide is located diametrically opposite to the 
cationic residues and contributes to the mechanism of elimination of 
pathogens provoking the formation of pores in the plasma membranes 
of pathogens. 
In the last years, a number of beta defensins have been studied; the best 
characterized are hBD-1, hBD-2, hBD-3 and hBD-4 (Schneider et al. 2005).  
hBD-1 was firstly isolated from a patient undergoing hemofiltration dialysis; 
later it has been later found in a large variety of tissues (Bensch et al. 1995, 
Valore et al. 1998). hBD-1 is expressed in that epithelia directly exposed to the 
external environment such as lung, mammary glands, salivary glands, kidney, 
pancreas and prostate (Pazgier et al. 2006, Hoover et al. 2001). hBD-1 is the 
only one defensin that can be expressed both in a constitutive or inducible 
manner. The latter, is consequent to exposure to bacteria or pro-
inflammatory cytokines (as interleukin-1β (IL-1β), tumour necrosis factor-α 
(TNF-α) and interferon- γ (IFN-γ) (King et al. 2002).  
A second family member, hBD-2, was firstly isolated from psoriatic scale 
extracts; successively it was found in lung, stomach, urogenital system and 
intestine (Seo et al. 2001, Wehkamp et al. 2002). hBD-2 is not expressed at 
basal level but it is inducible after exposition to bacteria, lipopolysaccharide 
and pro-inflammatory cytokines as TNF-α and IL-1β (King et al. 2002).  
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hBD-3 was initially isolated from epidermal keratinocytes from patients with 
psoriasis. It is induced by IFN-γ, TNF-α and bacteria in lung and intestine 
(Harder et al. 1997, Harder et al. 2001).  
Finally, hBD-4 was first isolated in lung tissues.  It is not expressed at basal 
level but can be up-regulated by Gram-negative and Gram-positive bacteria 
and by IFN-γ and TNF-α (Yanagi et al. 2005). hBD-3 and hBD-4 are expressed 
also in the endometrium (King et al. 2003).  
hBD-s possess two main activities: antimicrobial and chemotactic. 
hBD-s manifest antimicrobial activity against several microbes, including 
Gram-positive and Gram-negative bacteria, fungi and viruses (Pazgier et al. 
2006; Weinberg et al 2006). However, different hBDs are selective in their 
activity. hBD-1 is more active against Gram-negative bacteria, while hBD-2, 
hBD-3 and hBD-4 are also active against Gram-positive bacteria and yeast 
(Pazgier et al. 2006, Maisetta et al. 2006). Furthermore, hBD-1 and hBD-2 are 
sensitive to salt whereas hBD-3 is the only beta defensin salt-resistant. The 
salt resistance is a very important aspect in patients affected by Cystic 
Fibrosis: several studies have demonstrated that the system of beta defensins 
in the airway epithelium of these patients is completely inactivated by the 
high salt concentrations (Goldman et al. 1997). 
Thank to their chemotactic activity, beta defensins have been described as 
molecules that provide a link between innate and adaptive immune 
responses. Chemo attractant activity toward dendritic cells, memory T cells 
and mast cells has been reported for hBD-2 and hBD-3 (Pazgier et al. 2006) 
and both hBD-3 and hBD-4 are chemotactic toward monocytes (Garcia et al. 
2001; Harder 2001). The chemotactic activity of hBDs towards immune cells 
seems to be mediate by the binding of defensins to the chemokine receptors 
CCR6 and CXCR4 (Lehrer 2004, Yang et al. 1999). 
In addition to their antimicrobial and chemotactic activity, the beta defensins 
exhibit other properties as stimulation of the expression of cytokines and 
adhesion molecules by epithelial cells, histamine release from mast cells, 
interaction with complement and opsonisation of bacteria (Chaly et al. 2000; 
Durr et al. 2002).  
Thanks to their antimicrobial and chemotactic power, beta defenisns are 
attracting great attention for their potential use in the treatment of 
infections. In particular, the attention is to the design and the development of 
analogs of the wild type defensins with a higher activity (Antcheva et al. 2009, 
Cole et al. 2003, Hoover et al. 2003, Jung et al. 2011, Krishnakumari et al. 
2009, Scudiero et al. 2010, Taylor et al. 2007). 
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Fig. 3: Human Beta Defensins. Representation of hBD-s functions. 
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1.7 Mechanism of Action  
 
As already said, AMPs are able to directly kill pathogens. In particular, 
defensins have antimicrobial activity against bacteria, fungi and viruses, 
especially when tested under low ionic strength conditions. The antimicrobial 
activity of defensins is mainly carried out on metabolically active bacteria, 
while their action is weaker in regard to bacteria inactivated by the lack of 
nutrients or by the action of metabolic inhibitor. Although the killing 
mechanism of defensins is not yet clear, it seems that the permeabilization of 
target membranes is the crucial step in defensin-mediated antimicrobial 
activity.  
In fact, it has been shown that bacteria treated with defensins can be 
permeabilized by small molecules. Moreover, the conditions which interfered 
with permeabilization of bacterial membranes prevent the loss of viability of 
bacteria, indicating permeabilization mechanism for microbial killing 
(Lichtenstein 1991). Further, in experiments with artificial membranes 
characterized by the presence of negative charges, defensins formed channels 
(Wimley et al. 1994). All these observations are consistent with the idea that 
the insertion of defensin molecules into the membranes depends on 
electrostatic forces (Fujii et al. 1993). Moreover, the activity of defensins 
against artificial membranes was diminished in the presence of increased salt 
concentrations, supporting the importance of electrostatic forces between 
the anionic phospholipid headgroups and the cationic defensins (Wimley et al. 
1994).  
Considering these data, the most reliable mechanism of antimicrobial activity 
is the following: the positive residues of hBD-s interact with negative charges 
of plasma membranes of microorganisms through an electrostatic 
recognition. Successively, with the amphipathic portion, defensins penetrate 
into the lipid bilayer inducing the permeabilization of membranes (Fig. 4). This 
appears to be the lethal event (Sahl et al. 2005; Ganz 2003).  
However, stable pore formation is not the only mechanism of defensin 
pathogen killing. Probably, hBD-s are able to inhibit RNA, DNA and protein 
synthesis and induce the synthesis in epithelial cells of cytokines, as INFγ, that 
contribute to bacteria and viruses elimination. It is also possible that several 
mechanisms cooperate to induce pathogen death (Sass et al. 2010).  
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Fig. 4: Mechanism of killing of Human Beta Defensins. A model of the most accreditated 
mechanism of microorganisms killing by defensins. The positive charges of hBD-s (pink) 
bind negative residues of plasma membrane of pathogens. Successively, amphipathic 
portion of the peptide (green) intercalate the lipid bilayer, causing pores formation and 
cell death. 
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1.8 Aim of the Thesis  
 
Human Beta Defensins (hBD-s) are small cationic peptides that play an 
important role in immunity killing bacteria, viruses and fungi and exerting 
chemotaxis against dendritic cells, lymphocytes and monocytes. Thanks to 
their antimicrobial and chemotactic activity, hBD-s represent a good target to 
develop new therapeutic molecules.  
Previously, wild type, hBD-1, hBD-3 have been chemically synthesized and 
eight analogs have been designed selecting the tracts crucial for their activity 
(Scudiero et al, 2010). In fact, Scudiero et al demonstrated that the C-terminal 
domain of hBD-3 and the internal portion of hBD-1 are sequences necessary 
for the antibacterial, antiviral and chemotactic activity; furthermore 1C and 
3N resulted the analogs with higher activity respect to that of the wild type 
(Fig. 5). 
In the present work, we studied and tested a new analog as a potential 
pharmacological molecule with enhanced antimicrobial properties. To this 
aim, we designed 3NI, a new peptide carrying out the following features: (a) 
shorter total sequence (in order to provide greater stability and ability to 
penetrate bacteria and viruses); (b) the C-terminus portion of hBD-3 (crucial 
for the antimicrobial activity); (c) the inner portion of hBD-1 (crucial for the 
chemotactic activity).  
In addition, we investigated the three most relevant pharmacological 
properties of defensins: the antimicrobial activity, the stability in human 
serum and the potential cytotoxic effects.  
For the antimicrobial activity, we performed a Colony Forming Unit assay 
(CFU), and estimated the Minimum Inhibiting Concentration (MIC) of peptides 
on three bacteria strains, E. coli, P. aeruginosa, E. faecalis. Furthermore we 
tested the inhibition of infectivity of peptides on the Herpes simplex Virus 
Type 1.  
For the stability in human serum, we incubated peptides in human healthy 
serum and performed HPLC and MALDI-TOF analysis to evaluate the 
degradation rate after 35 min, 1h, 2 h, 4 h, 6 h and 24 h. 
For the cytotoxicity, we tested the effects of peptides on three human 
epithelial cell lines (A549, CaCo-2, Capan-1). We evaluated cell viability using 
MTT test, cell apoptosis using Annexin-V Propidium Iodine assay and DNA 
integrity using single cell gel electrophoresis assay. 
Finally, we labeled peptides with the fluorochrome NBD and performed 
confocal microscopy experiments on human epithelial cell lines to elucidate 
the mechanisms of interaction of peptides with plasma membranes. 
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Fig. 5: (A) Superimposition of hBD-1 (red) and hBD-3 (blue) polypeptide chains. The side 
chains of some charged residues (blue) and disulfide bonds (orange and yellow) are also 
shown. (B) Sequence alignments and net charges of hBD-1, hBD-3, and synthetic analogs. The 
disulfide connectivities among the consecutively numbered cysteins are shown at the top. 
The hBD-1 and hBD-3 regions that have been substituted in the analogs and that are 
underlined are N (amino-terminal peptide segment), I (internal domain between Cys3 and 
Cys4), and C (C-terminal peptide segment). The net charges for these segments are reported 
on the right. Conserved residues are marked by the vertical green bands; secondary structure 
elements are shown at the bottom in brown (alpha helix) and yellow (beta sheet). The 
coloured segments of sequences derive from hBD-1 (red) or hBD-3 (blue). (C) The coloured 
drawings in the boxed bars indicate the regions exchanged between hBD-1 and hBD-3. 
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2 Materials and Methods 
2.1 Design of Synthetic Peptides   
  
Peptides were synthesized using the standard solid-phase-9-
fluorenylmethoxycarbonyl (Fmoc) method as previously reported (Scudiero et 
al. 2010). The NovaSyn TGA (Merck, Darmstadt, Germany) resin (substitution 
0.25 mmol/g) was used as solid-phase support, and syntheses were 
performed on a scale of 100 μmol. Peptides were fully deprotected and 
cleaved from the resin with trifluoroacetic acid (TFA) with 5% thioanisole, 3% 
ethandithiol and 2% anisole as scavengers. The crude peptides were 
precipitated with ice-cold ethyl ether, filtered, dissolved in water, lyophilized, 
and reduced with dithiothreitol (DTT). Peptides were purified to homogeneity 
by preparative reverse phase-high pressure liquid chromatography (RP-HPLC). 
The samples were injected on a Phenomenex (Phenomenex, Torrance, CA, 
USA) C18 column (22 mm x 25 cm, 5 mm) eluted by H2O/0.1% TFA (A) and 
CH3CN/0.1% TFA (B) solvent mixture. A linear gradient from 5 to 50% of B 
over 17 minutes (min) at a flow rate of 20 ml/min was used. The collected 
fractions were lyophilized to dryness and analyzed by analytical RP-HPLC using 
a Phenomenex C18 analytical column (4.6 x 250 mm, 5 mm). The identity of 
purified peptides was confirmed by electron spray ionisation liquid 
chromatography-mass spectrometry (ESI LC-MS) using a Thermo Electron 
MSQ Surveyor.  
NBD labelling of peptides: Labelling was performed on resin-bound peptides 
as previously reported by Rapaport & Shai (Rapaport and Shai 1991). Briefly, 
30-70 mg of resin-bound peptide (10-25 mmol) was treated with piperidine in 
DMF in order to remove the Fmoc protecting group of the N-terminal 
aminoacid of the linked peptide. The resin-bound peptide was then reacted 
with 4-chloro-7-nitrobenz-2-oxa-1, 3-diazole (NBD-Cl) in DMF (3-4 equiv.). 
After 24 hours (h), the resin-bound peptides were washed thoroughly with 
methylene chloride, and the peptides were then cleaved from the resin and 
purified as previously reported for the non-labelled peptides. Under these 
conditions, a major product was obtained, possessing an NBD moiety 
attached to the peptide’s N-terminal amino group. The identity of this 
compound was confirmed by LC/MS.  
 
 
2.2 Antibacterial Assay  
       
A CFU assay of the antibacterial activity of hBDs against Pseudomonas 
aeruginosa ATCC (American Type Culture Collection, Manassas, VA, USA) 
27853, Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922 
was performed. The selection of these strains arose from the need to find 
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substances with increased activity of those endogenous and able to be active 
even in extreme conditions of ionic strength, as occurs for patients with 
Cystic Fibrosis. In fact, CF patients have lung fluid with high concentrations of 
NaCl. For this reason, tests were performed on the antimicrobial activity in 
normal and high salt concentration. The strains were grown in aerobic 
conditions in tryptic soy broth (Difco Laboratories, Detroit, MI, USA) at 37°C. 
The next day she applies a refreshment rate of the culture overnight with 
fresh medium and placed in incubation at 37° C with stirring until the 
exponential phase (determined by absorption spectrophotometer). At this 
point, 100 μl of this culture are centrifuged and subjected to a series of 
washes with 1 mM phosphate buffer in order to ward off the ground. After 
the last step, the cells were resuspended in 1 mM phosphate buffer 1000 μl. 
The experiments were carried out by taking 10 μl of this solution containing 
the cells, adding the solution of NaCl, water or phosphate buffer and 
defensins in order to reach a final volume of 200 μl for 2 h at 37*C in 
agitation. Controls were prepared as the experiments except the absence of 
defensins. We used two peptides concentrations, i.e., 2.5 µM and 12.5 µM. 
For salt dependence assay, NaCl in a range of concentrations i.e., 0, 50, 100 
and 200 mM NaCl, were included in the incubation buffer as previously 
described (Scudiero et al, 2010). Each assay was performed in triplicate. At 
the end of incubation, serial dilutions were plating onto agar plates. The 
count of the colony-forming units (CFU) was executed the next morning. 
Bactericidal activity (mean and SD of three assays) is expressed as the ratio 
between colonies counted and the number of colonies on a control plate. The 
minimal inhibitory concentration (MIC) of the new molecule 3NI was 
determined with a modified version of the microbroth dilution assay of the 
National Committee for Clinical Laboratory Standards using a final inoculum 
of 105 CFU/ml. The following peptide concentrations were used: 100.0, 50.0, 
25.0, 12.5, 6.25, 3.12 and 1.56 mM. 
 
 
2.3 Antiviral Assay  
        
Vero cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal calf serum. HSV-1 carrying a lacZ gene driven 
by the cytomegalovirus (CMV) IE-1 promoter to express beta-galactosidase 
was propagated as described (ref). All experiments were conducted in parallel 
with no-peptide controls. The effect of peptides on inhibition of HSV 
infectivity on cell monolayers were assessed: i) For “co-exposure” 
experiments, the cells were incubated with increasing concentrations of the 
peptides (1,5, 10.0, 20.0, 50.0, 100.0 and 250.0 μM) and with the viral 
inoculum for 45 min at 37°C. Non-penetrated viruses were inactivated by 
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citrate buffer at pH 3.0. Monolayers were fixed, stained with 5-bromo- 4-
chloro-3-indolyl-beta-D-galactopyranoside (X-gal) and plaque numbers were 
scored. Experiments were performed in triplicate and the percentage of 
inhibition was calculated with respect to no-peptide control experiments; ii) 
For “virus pre-exposure” experiments, approximately 2 x 104 PFU of HSV-1 
were incubated in the presence of 20 μM of peptides for 45 min at 37°C, then 
titrated on Vero cell monolayers; and iii) For “cell pre-exposure” experiments, 
Vero cells were incubated with 20 μM of peptides for 30 min at 4°C and 
infected with serial dilutions of HSV-1 for 45 min at 37°C. 
 
 
2.4 Cell Culture and Viability Assay   
   
Cell lines were obtained from the Bank of Human and Animal Continuous Cell 
Lines-CEINGE Biotecnologie Avanzate – Napoli- Italy. 
Parental A549 cells (human lung carcinoma) and parental CaCo-2 (human 
colon adenocarcinoma) stored in liquid nitrogen were thawed by gentle 
agitation of their vials for 2 min in a water bath at 37°C. After thawing, the 
content of each vial was transferred to a 75 cm2 surface area, tissue culture 
flask, diluted with 90% Dulbecco’s Modified Eagle’s Minimal Essential Medium 
(DMEM) (Sigma-Aldrich St. Louis. MO USA) supplemented with 10% foetal 
bovine serum (FBS) (Lonza Basel, Switzerland) and 1% L-glutamine (Sigma-
Aldrich St. Louis, MO USA). Parental Capan-1 cells (human pancreas 
adenocarcinoma) were growth with 80% RPMI 1640 Medium (Sigma-Aldrich 
St. Louis, MO, USA) supplemented with 20% FBS 1% L-glutamine. Then the 
cells were incubated for 24 h at 37°C in a 5% CO2 to allow them to grow and 
form a monolayer in the flask. Cells grown to 80–95% of confluence were 
washed with phosphate buffer saline (PBS), trypsinized with 3 ml of trypsin-
EDTA (ethylenediaminetetraacetic) solution (1X) (Sigma-Aldrich St. Louis. MO. 
USA), diluted, counted and seeded (4x103 cells/200 µl per well) into a 96-well 
ml tissue culture plates for 24 h in triplicate.  
The reduction of the proliferation of the cells was evaluated by the 3- [4.5-
dimethylthiazol-2-yl]-2.5-dipheniltetrazolium bromide (MTT) (Sigma-Aldrich 
St. Louis, MO, USA) assay, which allows measurement of metabolic changes 
(Liu et al. 1997). This assay is an excellent gauge of the cellular response to 
external factors such as synthetic molecules because it is used to test 
molecules that interfere with cell viability (Ferrari et al. 1990). The assay is 
based on the use of yellow tetrazolium salt (MTT), which are processed only in 
metabolically active cells by the action of enzymes dehydrogenase. The result 
is the production of NADH/NADPH and an intracellular purple precipitate 
(formazan). The solubilisation of the purple precipitate allows the 
quantisation of active cells by reading at a spectrophotometer. 
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Cells were incubated with or without beta-defensin peptides wild type 1 and 3 
and their analog molecules (1C, 3N and 3NI) according to different schemes: 
after 4, 8, 12, 16, 20, 24, 48 and 72 h of incubation at 37 °C at different 
concentrations i.e. 2.5, 12.5 and 25.0 μM. Adherent cells were stained with 
MTT dye solution i.e. 20 μl of 1:10 diluted MTT stock solution (5 mg/ml) and 
incubated for 4 h. After the incubation, the presence of the purple crystals 
that normally indicate the occurred metabolization of the MTT was verified. 
Then the medium was removed (180 μl) and 180 μl of Dimethyl Sulfoxide 
(DMSO) (Sigma-Aldrich St. Louis, MO, USA) was added to dissolve the MTT 
crystals. The eluted specific stain was measured by a spectrophotometer (550 
nm). The experiments were performed in triplicate. The proliferation index of 
the untreated cells was compared to the negative controls (cell + medium 
without peptides) that represent 100% viability and were included as a 
control in all experiments to allow estimation of the percentage viability of all 
the cell samples.  
 
 
2.5 Apoptosis Assay   
       
To identify the number of cells that undergo programmed cell death after 
incubation with the wild type and chimeric peptides, we performed the 
apoptosis assay using the kit "Annexin V-FITC Apoptosis Detection Kit 1" (BD 
bioscience). The cells used for this test were A549, Caco2 and Capan-1. The 
apoptotic program is characterized by several functional and morphological 
changes including: 
• Disruption of the plasma membrane 
• Condensation of the cytoplasm and the nucleus 
• DNA fragmentation 
The loss of the plasma membrane integrity is a phenomenon observed from 
the early stages of apoptosis: phosphatidylserine (PS), a component of the 
membrane, is translocated from inside to outside the cell. Annexin-V is a 
protein that bind phospholipids in a calcium-dependent manner and that has 
a high affinity for PS. Consequently, it is able to bind with good specificity of 
the apoptotic cells that have exposed PS on the surface. Because the 
exposition of PS on the plasma membrane is an early stage of apoptosis, it is 
certainly possible to identify cells that have programmed apoptotic death 
even before the phenomenon is complete. The revelation of the "convicted" 
cells take place through a fluorescent staining (V-FITC), which guarantees a 
high sensitivity for the test followed by the analysis of fluorescence by flow 
cytometry. In association, another staining is used to identify death cells or in 
late apoptosis (Propidium Iodine (PI)). The viable cells with intact cell 
membranes exclude the PI; on the contrary damaged cells are instead 
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permeable. Specifically, therefore, the test allows to use a double standard 
for cell selection, one positive and one negative, which allows to distinguish 
viable cells from those in early apoptosis and those death. The pattern of 
reactivity is as follows: 
• Living cells: V-FITC and PI negative 
• Early apoptotic cells: Annexin V-FITC positive and PI negative 
• Necrotic or apoptotic cells, terminal: V-FITC and PI positive 
The test cannot distinguish between cells that have died by apoptosis or 
necrosis. The result of the assay is quantitative, as a percentage. 
Exponentially growing A549, CaCo-2 and Capan-1 cells were trypsinized and 
plated at density of 1 x 105 cells per ml per 24-well plate and allowed to 
attach for 24 h. On the next day, cells were exposed to three different 
concentrations (i.e. 2.5, 12.5 and 25.0 µM) of wild type peptides hBD1 and 
hBD3 and their analogs 1C, 3N and 3NI for 24, 48 and 72 h. After incubation 
times, cells were spinned 5 min at 1300 rpm and then resuspended in 100 μl 
of Annexin-V Binding Buffer 1X (Becton Dickinson), 5 μl of Annexin-V-FITC 
(Becton Dickinson) and 5 μl of PI (50 μg/ml) were added. Cells were stained 15 
min at room temperature and then 400 μl of Annexin-V binding buffer were 
added before acquisition. The results were interpreted as follows: cells 
negative for both PI and Annexin-V-FITC staining were considered live cells; PI-
negative, Annexin-V-FITC-positive stained cells were considered in early 
apoptosis. Negative controls (cells+medium without peptides) were included 
as a control in all experiments to allow estimation of the percentage of 
apoptotic and death cells. 
 
 
2.6 DNA Damage Assay  
     
The Comet assay is an excellent gauge of the cellular response to external 
factors such as synthetic molecules because it is used to test molecules that 
interfere with DNA integrity (McKelvey-Martin et al. 1998; Speit et al. 2004). 
The DNA strand breakage was defined using comet assay kit form Trevigen 
(Gaithersburg MD). The cells used for this test are A549, Caco2 and Capan-1. 
For the determination of DNA strand breakage, exponentially growing cells 
were trypsinized and plated at density of 1 x 105 cells per ml per 24-well plate 
and allowed to attach for 24 h. On the next day, cells were exposed to two 
different concentrations (i.e. 2.5 and 12.5 µM) of wild type peptides hBD1 and 
hBD3 and their analogs 1C, 3N and 3NI for 4 and 24 h. At the end of 
incubation time, cells are resuspended in 50μl of 1x PBS. The suspension is 
then mixed with 500 μl of agarose melted at 37° C; 75 μl of this mixture must 
be immediately entered in special slides, the "Comet Slide". The slides are left 
for 10 min at 4 ° C in the dark, and then immersed in a lysis solution for 30-60 
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min. The next step consists of immersing the slides in an alkaline solution for 
20-60 min. Finally after electrophoresis (electric field of 1 volt per cm for 10 
min), the slides are stained with SYBR green and read the fluorescence 
microscope. The maximum absorption and emission of SYBR green are 494nm 
and 521nm respectively. In intact cells the fluorescence emission is confined 
to the nucleus: the undamaged DNA is supercoiled and this allows only a weak 
migration of the nucleic acid within the nucleus. In cells in which DNA is 
damaged, treatment with an alkaline solution allows the relaxation of DNA 
fragments and therefore a greater degree of migration. All the steps were 
conducted under yellow lamp in the dark to prevent additional DNA damage. 
Stained slides are viewed under automated robotic epifluorescent 
microscope. Experiments were performed in triplicate. 
We compared our data with a positive control that cause DNA breakage 
(A549, CaCo-2 and Capan-1 cell lines treated with H2O2 250 μM for 30 min and 
Etoposide 60 μM for 1 hour) and a negative control (untreated cells).  
 
 
2.7 Confocal Microscopy   
     
A549 and CaCo-2 cells were seeded at 25% confluence in IBIDI 6 wells 
chambers (Ibidi GmbH) in DMEM containing FBS 10%, at 37°C and 5% CO2 
(“growth conditions”), and used for the experiments after 36 h of growth. 
In pulse and chase confocal based experiments, cells were incubated in 15 µM 
of each NBD-labelled defensin for 10 min at 37°C and 5% CO2 (“pulse”); 
subsequently, defensin-containing medium was substituted with fresh growth 
medium (“chase”) and cells were incubated at 37°C, 5% CO2, for variables 
times. After chase times, cells were immediately fixed with PFA 3.7% in PBS 
and stained without permeabilization steps. WGA-Al555 and DAPI were used 
as marker of plasma membrane (PM) and nuclei, respectively. In experiments, 
FM4-64FX (Invitrogen) was used as vital/fixed cell marker of plasma 
membranes. “Mild pre-fixation” of A549 cells consisted of 1.8% PFA in PBS, 2 
min at room temperature. 
Immunofluorescence assays were performed with the primary antibody anti 
EEA1 (Early Endosome Antigen 1; Affinity bioreagent), which is a marker of 
early endosomes. A549 cells and CaCo-2 were treated with 15 µM each 
defensin for 10 min, followed by wash with growth medium and incubation 
for 0, 15 min, 30 min, 1 hour, 1.5 h and 2 h in growth conditions. Cells were 
then fixed with PFA 3.7% in PBS, permeabilized by PBS/triton x100 0.1% 10 
min at room temperature, blocked by BSA1%/PBS for 30 min, and treated 
with EEA1 antibody 1:100 in BSA1%/PBS for 30 min at room temperature, 
followed by secondary Alexa 546 conjugated antibody treatment (Invitrogen). 
LysoID (Enzo Life Sciences) was used as follows: A549 and CaCo-2 cells were 
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treated with 15µM of each defensin for 10 min in growth conditions, and then 
washed with growth medium and incubated in growth conditions for 1 and 4 
h. Cells were then incubated with LysoID working solution for 15 min, washed 
once with growth medium, and immediately imaged by confocal microscopy. 
Experiments were performed in triplicate. 
Microscope was LSM 510 meta confocal microscope (Carl Zeiss, Jena) 
equipped with an oil immersion planapo 63x objective 1.4 NA. Used settings 
were the following: green channel for detecting NBD, excitation 488nm argon 
laser, emission bandpass filter 505-550nm; red channel for detecting WGA-
Alexa555, FM4-64FX and LysoID, excitation 543 nm Helium/Neon laser, 
emission bandpass filter 560-700nm (by using the meta monochromator); 
blue channel for detecting DAPI, excitation 405nm blue diode laser, emission 
bandpass 420-480 nm.  
 
 
2.8 Serum Stability  
       
50 μg of wild type hBD3 were incubated with 250 μl of untreated human 
serum from healthy donors [25% (v/v) in PBS] at 37°C for 24 h. Aliquots of 25 
μl, corresponding to 5μg of peptide, were added to 65 μl of cold 0.5% (v/v) of 
TFA (trifluoroacetic acid) in water at different time intervals (0, 0.5, 1, 2, 4, 6 
and 24 h), kept on ice for 5 min and then centrifuged at 16200 g for 5 min. 
The supernatants were analyzed using a reverse phase high performance 
liquid chromatography, RP-HPLC (Perkin Elmer), followed by MALDI-TOF mass 
spectrometry analysis with a Voyager DE-STR (Applied Biosystem). The 
components were separated using a Jupiter C18 column 5 μm particle size, 
300 Å pore size, 250x2 mm (Phenomenex) with a flow rate of 0.2 ml/min and 
a linear gradient from 20 to 60% of solution B (0.1% TFA in acetonitrile) and 
solution A (acidified water 0.1% TFA) for 25 min. The percentage of the intact 
peptide (P) was calculated from the area of the corresponding peak in the 
chromatogram (P=At/A0 x100); At is the peak area of the peptide at any given 
time; A0 is the peak area at time zero. The MALDI-TOF was operated in the 
linear mode using a matrix solution of α-Cyano-4-hydroxycinnamic acid 10 
mg/ml (TFA 0.2% in 70% ACN). Externally mass spectrometer calibration was 
performed using a protein mixture of Insulin, Myoglobin and Cytocrome C. 
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3 Results and Discussion    
3.1 Design of the Novel Synthetic Peptide 3NI   
  
We previously synthesized and reported the antimicrobial and chemotactic 
activities of eight analogs obtained from hBD1 and hBD3 (Scudiero et al. 
2010). We were able to identify the peptides and/or their domains that 
exerted the most potent antibacterial, antiviral and chemotactic activities. 
Two of these peptides, i.e., analogs 1C and 3N, were the best suited, in terms 
of maximizing antimicrobial activity also in the presence of high NaCl 
concentrations. This finding showed that both the charged C-terminal domain 
of hBD3 and the internal domain of hBD1 played a fundamental role in the 
analog’s antimicrobial activity. In the present study we designed a novel 
chimeric molecule 3NI analogue to hBD3 without the N-terminal domain of 
hBD3 and comprising the internal domain of hBD1 (Fig. 6). Successively, we 
tested the antibacterial and antiviral activity of the novel molecule 3NI. 
 
 
 
 
Fig. 6: Sequence alignments of hBD1, hBD3 and synthetic analogs 3NI, 3N and 1C. The 
coloured segments of sequences derived from hBD-1 (red) and hBD-3 (bleu). The coloured 
drawings in the boxes bars indicate the regions exchanged between hBD1 and hBD3.  
3NI sequence: KYYCRVRGGRCAVLSCPIFTKIQGTCSTRGRKCCRRKK 
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3.2 Antibacteial Assay    
     
In order to investigate the activity of the new analog 3NI, we performed an 
antibacterial assays (CFU and MIC) using 3NI analog against P. aeruginosa, E. 
coli and E. faecalis. We previously reported the antibacterial activity of hBD1 
and hBD3 (Scudiero et al. 2010). Furthermore, in the present study, in order 
to test the antibacterial activity of 3NI, hBD1 and hBD3 have been considered 
as positive controls. We used two concentrations of each peptide (2.5 and 
12.5 µM) and four concentrations of NaCl (0, 50, 100 and 200 mM). The 
antibacterial activities of all peptides against P. Aeruginosa (Fig. 7, panel A), E. 
coli  (Fig. 7, panel B) and E. faecalis (Fig. 7, panel C) were comparable. At a 
concentration of 2.5 µM, the antibacterial activity of hBD1 was strongly 
inhibited at a NaCl concentration as low as 50 mM (p< 0.001). On the 
contrary, the antibacterial activity of hBD3 was not inhibited within 200 mM 
NaCl (p<0.001). Considering hBD3 as reference wild type defensin because of 
the high salt-resistance, our new analog 3NI at a concentration of 2.5 µM 
maintained good antibacterial activity up to a 100 mM of salt. At 12.5 µM, 
3NI is active up to 200 mM NaCl.  
In addition, we performed the MIC of 3NI with the conventional micro-broth 
dilution assay. The MIC values ranged between 12.5–25.0 mM for all the 
tested microorganisms. Peptides hBD1, hBD3 and the 3NI analog exerted a 
strong antibacterial effect against P. aeruginosa, E. coli and E. faecalis (12.5 
mM). 
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Fig. 7: Antibacterial activity of wild type hBD-1 and hBD-3 and the novel analog 3NI. The 
results are mean and SD of three replicates for each assay; all peptides were tested at two 
concentrations (2.5 and 12.5 µM) against P.aeruginosa (A), E. coli (B) and E. faecalis (C) at 
different NaCl concentrations (0, 50, 100, 200 mM). Error bars show the SD of experiments 
performed in triplicate. 
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3.3 Antiviral Assay  
       
In order to investigate the activity of the new analog 3NI, we performed an 
antiviral assay of 3NI. We measured and compared the activity of 3NI with 
previously determined activities obtained for hBD1, hBD3, 1C and 3N. All 
peptides dose-dependently inhibited HSV infectivity (Fig. 8). Analog 3NI had 
no residual infectivity at 50 μM; the data are comparable with those obtained 
for hBD3 (no residual infectivity at 50 mM). At the same concentration, the 
residual infectivity for analogs 3N and 1C was 10% and 34 %, respectively.  
Peptide hBD1 displayed a lower compared to hBD3 and 3NI antiviral activity at 
50 μM. 
 
 
Fig. 8: Antiviral activity of wild type hBD-1 and hBD-3 and the novel analog 3NI. All peptides 
were tested against herpes simplex virus type 1 at a concentration of 20.0 µM after different 
treatments (see also materials and methods). Error bars show the SD of experiments 
performed in triplicate. 
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3.4 Viability Assay  
       
The MTT test was performed to evaluate the cytotoxic effect of hBD wild type 
1 and 3 and their analogs 1C, 3N, 3NI on three human epithelial cell lines: lung 
carcinoma (A549); colon carcinoma (CaCo-2); pancreas carcinoma (Capan-1). 
We tested three concentrations of peptide  (2.5, 12.5 and 25.0 µM) and eight 
incubation times (0, 4, 8, 12, 16, 20, 24, 48 and 72 h) (Fig. 9, panles A-I). 
The results obtained for A549 cells are shown in Fig. 4 (panels A, B, C). During 
exposure between 4 h and 24 h, cell viability unchanged. After 24 h of 
exposure, the percentage of reduction of the proliferation induced by hBD1 
and hBD3 wild type is comparable to that of their analogs 1C, 3N and 3NI. The 
percentage of the reduction of proliferation was < 10% at all concentrations 
tested (2.5, 12.5 and 25.0 µM). After 48 h of exposure, peptides reduced cell 
viability between 4-12% for the three concentrations tested. After 72 h cells 
hBD1, hBD3 wild type and their analogs 1C, 3N, 3NI at 2.5 µM reduced cell 
viability of 30%, while for the concentrations of 12.5 and 25.0 µM, the 
reduction ranged between 28-30%. Between 4 h and 72h of incubation of 
cells with the peptides, a cell viability reduction higher than 30% was never 
observed.  
Figure 9 (panels D, E, F) shows the effects of the peptides on CaCo-2 cells. As 
observed for A549 cells, there was no reduction in cell viability between 4 and 
24 h of exposure of cells to the peptides. After 24 h of exposure, the peptides 
at a concentration of 2.5 µM, caused a reduction in cell viability of 2%, while 
at a concentration of 12.5 and 25.0 µM, the reduction of viability was 
between 5 and 10%. After 48 h until 72 h of incubation, all the peptides tested 
reduced viability of 4-12%. During the time course between 4 h and 72 h of 
incubation of the cells with the peptides a reduction of cell viability greater 
than 20% was never observed.  
The MTT results of hBD-s wild type 1 and 3 and their analogs 1C, 3N, 3NI on 
Capan-1 cells is shown in Fig. 9 (panels G, H, I). As observed for A549 and 
CaCo-2 cells, there was no reduction in cell viability between 4 and 24 h of 
exposure of cells to the peptides. After 24 h of exposure, the reduction in 
viability ranged between 8-16% for all the concentrations tested (2.5, 12.5, 
25.0 µM). After 48 h of incubation, the reduction in cell viability was between 
11-17%, while after 72 h a reduction ranged between 18 and 24%.  
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Fig. 9: Effect of hBD-1, hBD-3 wild type and their analogs 1C, 3N, 3NI on cell viability. Three 
different concentrations tested: 2.5 μM (panel A, D, G); 12.5 μM (panel B, E, H); 25.0 μM 
(panel C, F, I) on the proliferation of the three different cell lines: A549 (panel A, B, C), CaCo-2 
(panel D, E, F) and Capan-1 (panel G, H, I). After 0, 4, 8, 12, 16, 20, 24, 48 and 72 h of 
incubation, adherent cells were stained with MTT dye solution. The eluted specific stain was 
measured by a spectrophotometer (550 nm). The data are expressed as peptide proliferation 
index compared to negative controls values. The data are expressed as the means +/- SD of 
two experiments performed in triplicate. 
 
 
In conclusion, all the peptides behaved similarly for all the concentrations 
tested (2.5, 12.5 and 25.0 µM). During the time course between 4 and 72 h of 
incubation of the cells with the peptides we never observed a reduction of cell 
viability greater than 30% for all the tested human cell lines (a549, CaCo-2, 
Capan-1).  
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3.5 Apoptosis Assay   
       
In order to evaluate if the reduction of cell viability observed by MTT test was 
mediated by apoptotic events, we performed the AnnexinV-Propidium Iodine 
assay. The flow cytometric analysis of the test gets two plots: the first allows 
assessing the size (FSC-A) and the degree of cell complexity (SSC-A) (Fig. 10); 
the second plot allows estimating the percentage of apoptotic cells. 
Looking at the first plot, it is important to note that the lower part of the plot 
represents the cells of small size and low cytoplasmatic complexity. In this 
region the number of recorded events, increases proportionally to the 
increase of the phenomenon of apoptosis and necrosis. This increase is 
caused by the presence of cellular debris produced by necrotic and apoptotic 
cells. 
 
 
 
 
Fig. 10: Dot plot resulting from the flow cytometry. The plot allows assessing the size (FSC-A) 
and the complexity of the cells (SSC-A). 
 
 
The second plot allows estimating the percentage of apoptotic cells induced 
by wild type and chimeric peptides (Fig. 11). 
The chart is divided into four quadrants: 
1. Q1 represents cellular artefacts; 
2. Q2 represents the late apoptotic cells, positive for the staining with 
both Annexin and Propidium Iodine;  
3. Q3 represents living cells, negative for the binding of both Annexin-V 
and Propidium Iodine; 
4. Q4 represents the early apoptotic cells, positive for Annexin-V 
binding.     
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Fig. 11: Dot plot resulting from the flow cytometry. Dot plots of untreated cells (a) and cells 
treated with the peptides (b). 
 
 
The analysis of the obtained plots allows to determine the percentage of cells 
in early apoptosis (Q4) and late (Q2). Flow cytometric analysis did not reveal 
any relevant apoptotic effect after the incubation of the hBD-s wild type 1, 3 
and their analogs (1C, 3N, 3NI) with the three human cell lines: A549 (Table 1), 
CaCo-2 (Table 2) and Capan-1 (Table 3) at the three concentrations i.e. 2.5µM, 
12.5µM and 25.0 µM for 24, 48, and 72 h. 
 
        Q2: %         
[peptides] 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
NC 1,2 1,2 1,2 1,4 1,4 1,4 2,3 2,3 2,3 
hBD1 2 2,2 2,7 1,4 2,2 2,1 0,8 1 0,9 
hBD3 3,6 2,9 4,5 1,5 2,2 3,6 0,8 2 3,7 
1C 2,2 1,7 2,3 3,2 2,5 2,9 1,6 1,6 1,2 
3N 2,2 1,6 3,4 4,2 3,3 4,8 1,3 2,1 1,5 
3NI 1,9 1,8 1,1 4,7 5,7 14,3 2 2,2 2,7 
incubation 
time (h) 
  24     48     72    
 
Table 1: Effect of synthetic peptides (hBD-1, hBD-3, 1C, 3N, 3NI) on apoptosis in A549 cells. 
Cells were incubated for 24, 48, 72 h with all peptides at different concentrations: 2.5, 12.5 
and 25 µM. Apoptosis was characterized by exposure of phosphatidylserine with Annexin-V 
labelling. Data are expressed as a percentage of Annexin-V positive and Propidium Iodine 
negative cells (Q2 on the scatter) after subtraction of negative control (untreated cells). All 
the synthetic peptides do not reveal a significant increase in the number of apoptotic cells 
when compared to untreated cells. NC: negative control. Experiments performed in triplicate. 
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       Q2: %         
[peptides] 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
NC 4,2 4,2 4,2 6,6 6,6 6,6 6,3 6,3 6,3 
hBD1 7,1 10,3 9,6 6,1 6,2 7 8,2 7,5 4,1 
hBD3 12,6 12,8 20,8 8,7 6 34,1 9,2 7,6 9,8 
1C 9 12,3 11,7 7,8 13,6 20,6 5,2 10,9 8 
3N 8,2 12,3 12,9 10,8 10,3 10,1 6 5,9 9,1 
3NI 6,6 9,2 14,3 7,5 6,2 14,2 7,3 6,3 6,2 
incubation 
time (h) 
  24     48     72   
 
Table 2: Effect of synthetic peptides (hBD-1, hBD-3, 1C, 3N, 3NI) on apoptosis in CaCo-2 cells. 
Cells were incubated for 24, 48, 72 h with all peptides at different concentrations: 2.5, 12.5 
and 25 µM. Apoptosis was characterized by exposure of phosphatidylserine with Annexin-V 
labelling. Data are expressed as a percentage of Annexin-V positive cells and Propidium Iodine 
negative (Q2 on the scatter) after subtraction of negative control (untreated cells). All the 
synthetic peptides do not reveal a significant increase in the number of apoptotic cells when 
compared to untreated cells. NC: negative control. Experiments performed in triplicate. 
 
 
       Q2: %        
[peptides] 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
2,5 
µM 
12,5 
µM 
25,0 
µM 
NC 15,2 15,2 15,2 10,2 10,2 10,2 19,6 19,6 19,6 
hBD1 14,4 12,6 12,9 17,8 11,3 10,7 15,1 8,1 17,2 
hBD3 14 8,3 9,2 10,9 14,8 18,7 10,8 15,9 26,2 
1C 9,2 12,3 14 16,1 16,2 16,2 21 18 22 
3N 8,4 7,4 16,7 14,7 12,5 11,2 12,8 25,2 22,3 
3NI 10,7 15,5 13,1 15,4 16,9 23,4 25,6 24,5 31,8 
incubation 
time (h) 
  24     48     72   
 
Table 3: Effect of synthetic peptides (hBD-1, hBD-3, 1C, 3N, 3NI) on apoptosis in Capan-1 cells. 
Cells were incubated for 24, 48, 72 h with all peptides at different concentrations: 2.5; 12.5 
and 25 µM. Apoptosis was characterized by exposure of phosphatidylserine with Annexin-V 
labelling. Data are expressed as a percentage of Annexin-V positive cells and Propidium Iodine 
negative (Q2 on the scatter) after subtraction of negative control (untreated cells). All the 
synthetic peptides do not reveal a significant increase in the number of apoptotic cells when 
compared to untreated cells. NC: negative control. Experiments performed in triplicate. 
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3.6 DNA Damage Assay 
 
The comet assay is routinely used to study the extent DNA damage in drug-
treated cells. We tested the effect of the wild type peptides hBD1 and hBD3 
and their analogs 1C, 3N, 3NI on A549 cells (Fig. 12, panel A), CaCo-2 cells (Fig. 
12, panel D) and Capan-1 cells (Fig. 12, panel G). As positive controls, we 
incubated cells with H2O2 (250 μM for 30 min) and observed the characteristic 
comate. After 4 h and 24 h of exposure to a peptide concentration of 2.5 and 
12.5 μM, we observed intact nuclei in each cell line tested. Our results 
demonstrated that all peptides do not induce DNA damage. 
 
 
Fig. 12: Comet assay on A549, CaCo-2, Capan-1 cells. Panels A, D, G: representative image for 
the results obtained for the wild type hBD-1, hBD-3 and analogs 1C, 3N, 3IN at two different 
concentrations (2.5 and 12.5 μM) and two different incubation times (4, 24 h) of A549, CaCo-
2 and Capan-1 cells respectively. Panels B, E, H: positive control of A549, CaCo-2 and Capan-1 
cells respectively (cells treated with H2O2 250 μM for 30 min). Panels C, F, I: negative control 
of A549, CaCo-2 and Capan-1 cells respectively (untreated cells). One representative image 
obtained in three independent experiments. All the synthetic peptides do not induce DNA 
damage. 
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3.7 Confocal Microscopy  
      
To study the interactions of our molecules with eukaryotic cells, we used two 
cell lines, A549 and CaCo-2. Capan-1 cells were not included in these 
experiments because of their autofluorescence. The confocal microscopy 
experiments were performed using NBD-labelled molecules. NBD was chosen 
because it is a small fluorescent molecule and therefore we supposed that it 
would have a minimal effect on the activity of defensins. A set of confocal 
microscopy experiments in fixed and in vivo cells were performed to 
investigate the mechanisms of interaction and internalization into cell plasma 
membranes. Cells were treated with peptides and then chased at several time 
points. After each chase time, cells were fixed and stained with WGA-Al555 
and DAPI, as markers of plasma membrane and nuclei, respectively. All the 
fluorescent NBD-labeled defensins displayed a comparable behaviour in these 
time-course experiments. Similarly, no significant differences were found 
between the two cell lines. Immediately after incubation with peptides, cells 
were washed to remove unbound molecules. At time 0 fluorescence was 
clearly localized only on the plasma membrane as indicated by the 
colocalization with the plasma membrane marker (Fig. 13, panel A). After 2 h, 
fluorescence appeared in cytosolic vesicles as shown by the ring-shaped 
fluorescence pattern obtained from the optical slices (Fig. 13, panel B). After 8 
h, the vesicle pattern did not change significantly (Fig. 13, panel C). After 18 h, 
a reduction of peptide fluorescence and of the number of vesicles occurred 
(Fig. 13, panel D). These results indicate that within 10 min, defensins were 
able to bind cell plasma membranes, in the subsequent 2 h, they were 
internalized in vesicles, and within 8 and 18 h, clearance of peptides had 
started. 
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Fig. 13: Interaction of A549 and CaCo-2 cells with defensins. Cells were treated with 15 µM of 
each defensin for 10 min; upon wash with fresh growth medium, they were incubated for 0, 
2, 8 and 18 h. Immediately after the proper times, cells were PFA fixed and stained with WGA-
Al555 and DAPI to localize plasma membrane and nuclei. Images represent single optical 
slices 1µm thick. Defensin is green, PM is red and Nuclei are blue; colocalizing regions appear 
orange-yellow in the overlay image. The five defensins in A549 and CaCo-2 cells behaved very 
similarly, therefore we show representative images of A549 treated with hBD-3. At time zero, 
defensins localized exclusively to the plasma membrane (panel A). After 2 and 8 h (panels B 
and C), defensins were found mainly internalized as vesicles. After 18 h (panel D), some 
vesicles are still apparent but reduced in number and intensity respect to previous times. 
Scale bar: 5µm. Experiments were repeated three times and images were acquired from at 
least 100 cells per experiment.  
 
 
Successively, to evaluate the mechanisms of internalization, we conducted a 
set of in vivo experiments using FM4-64FX, a marker of the plasma 
membranes and endocytosis. Our peptides colocalized with FM4-64FX (Fig. 
14). Because FM4-64FX binds immediately to the outer leaflet of plasma 
membrane and is internalized by endocytosis, our data suggest that cells by 
means of this process internalized defensins. 
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Fig. 14: Defensins are internalized by endocytosis. Cells were treated with 15 µM of each 
defensin and FM4-64FX, which is a marker of plasma membrane, for 2 h. Upon wash with 
PBS, they were immediately PFA fixed and imaged by confocal microscope.  Images represent 
single optical slices 1µm thick. Defensin is green, Plasma membranes and endosomes are red; 
colocalizing regions appear orange-yellow in the overlay image. The five defensins in A549 
and CaCo-2 cells behaved very similarly, therefore we show representative images of A549 
treated with hBD-3. Defensins colocalized extensively with endosomes. Scale bar: 5µm. 
Experiments were repeated three times and images were acquired from at least 100 cells per 
experiment. 
 
To clarify which kind of mechanism contribute to defensins internalization, if 
an active or a passive mechanism occur. To this aim, we carried out 
experiments with a mild “pre-fixation” of cells before the incubation of the 
cells with peptides.  Within 10 min, our molecules localized with the plasma 
membrane (data not shown) and remained in this compartment also after 2 h 
(Fig. 15). These data indicate that, association to the plasma membrane did 
not require an active mechanism while the internalization required it.  
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Fig. 15: When active mechanisms are blocked defensins remain in the plasma membrane. 
Cells were mildly PFA prefixed to kill active mechanisms and then treated with 15 µM of each 
defensin and FM4-64FX, a marker of plasma membrane for 2 h. Confocal images represent 
single optical slices 1µm thick. Defensin is green, FM4-64 is red; colocalizing regions appear 
orange-yellow in the overlay image. The five defensins in A549 and CaCo-2 cells behaved very 
similarly, therefore we show representative images of A549 treated with hBD-3. Defensin 
colocalized with FM4-64 which was found exclusively on the plasma membrane. No defensin 
and FM4-64 fluorescence was detected in the cell interior. Scale bar: 5µm. Experiments were 
repeated three times and images were acquired from at least 100 cells per experiment.  
 
To further verify that endocytosis mechanisms are required for defensins 
internalization, we carried out experiments at 4°C that block active 
mechanisms. After 2 h, no fluorescence was observed inside the cells (Fig. 16), 
which suggests that endocytosis was indeed the mechanism involved in 
internalization. 
 
 
 
Fig. 16: When endocytosis is blocked, defensins are retained on the plasma membrane. Cells 
were treated with 15 µM of each defensin for 2 h on ice. Ice temperature is known to block 
endocytosis. Cells were PFA fixed immediately after ice incubation. Confocal images represent 
single optical slices 1µm thick. Defensin is green, DAPI is blue. The five defensins in A549 and 
CaCo-2 cells behaved very similarly, therefore we show representative images of A549 
treated with hBD-3. Defensin localized exclusively on the plasma membrane. No defensin 
fluorescence was detected in the cell interior. Scale bar: 5µm. Experiments were repeated 
three times and images were acquired from at least 100 cells per experiment. 
 
 
Since we demonstrated that active mechanisms of endocytosis are 
responsible for defensins internalization in the cells, we investigated if early 
endosomes are involved in this process. To this aim, we performed 
immunofluorescence assays using the antibody anti EEA1, a marker of early 
endosomes, upon pulsing of cells with each peptide, and chasing for several 
times. Peptide fluorescence partially colocalized with EEA1 already after 15 
min (Fig. 17, panel B) and the extent of colocalization increased within 2 h 
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(Fig. 17, panel A), suggesting that early endosomes are involved in peptide 
processing.  
 
Fig. 17: Defensin containing endosomes docks on early endosomes. Cells were treated with 
15 µM of each defensin for 10 min; upon wash with fresh growth medium, they were 
incubated for 2 h, PFA fixed, permeabilized and stained by immunofluorescence with 
antibody anti EEA1, marker of the early endosome compartment, and DAPI for nuclei. 
Confocal images represent single optical slices 1µm thick. Defensin is green, AntiEEA1 is red, 
DAPI is blue; colocalizing regions appear orange-yellow in the overlay image. The five 
defensins in A549 and CaCo-2 cells behaved very similarly, therefore we show representative 
images of A549 treated with hBD-3. Defensin colocalized partially with early endosomes 
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already after 15 min (panel B) and with higher extent after 2 h (panel B). Scale bar: 5µm. 
Experiments were repeated three times and images were acquired from at least 100 cells per 
experiment. 
  
In addition to further discuss our data, LysoID have been used to mark 
lysosomes in vivo experiments; the cells have been pulsed with each peptide, 
chased and then stained for lysosomes. LysoID fluorescence was partially 
colocalizing with that of our molecules after 1 and 4 h, indicating that at least 
some of the peptide-containing vesicles were targeted to lysosomes (Fig. 18).  
Therefore, degradation processes of our molecules partially occur by means 
of lysosomes. We cannot exclude that others mechanisms participate too 
defensins disposal from the cells. 
 
 
Fig. 18: Defensin vesicles localize to lysosomes. Cells were treated with 15 µM of each 
defensin for 10 min; upon defensin removal, cells were incubated for 4 h in fresh growth 
medium. Before observation cells were treated with LysoID, which stains lysosomes. Confocal 
images represent single optical slices 1µm thick of live cells. Defensin is green, LysoID is red; 
colocalizing regions appear orange-yellow in the overlay image. The five defensins in A549 
and CaCo-2 cells behaved very similarly, therefore we show representative images of A549 
treated with hBD-3. Defensins colocalized partially with lysosomes already after 4 h. Scale 
bar: 5µm. Experiments were repeated three times and images were acquired from at least 
100 cells per experiment. 
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3.8 Serum Stability 
 
Since we proposed these peptides as therapeutic target for the treatment of 
infectious diseases, our attention focused on the study of the stability of these 
peptides in human serum. In fact, demonstrated their antimicrobial activity, 
and assuming an employment in the treatment of infectious state, we wanted 
to understand firstly the stability of wild type hBD-3.  
We found from 0 min until 1 h, no degradation of peptide. After 2 h, hBD-3 is 
degraded of about 30% and finally from 4 h until 24h around 45% (Fig. 19). 
 
 
  
Fig. 19: Stability profiling of hBD-3 in human serum from an healthy donor. 25% (v/v) of 
untreated human serum in PBS incubated with hBD-3.    
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3.9 Discussion 
 
The production of AMPs plays a fundamental role in defense against 
infections (Wiesner et al. 2010). We previously designed and characterized 
the biological activities of two hBD-1 and hBD-3 analogs, namely, 1C and 3N 
(Scudiero et al. 2010). We demonstrated a higher salt resistance of the two 
newly designed analogs compared to the wild type. 
The superimposition of the three-dimensional structures of hBD-1 and hBD-3 
showed that the main differences between the two molecules were in the N-
terminal region, the C-terminal region and the internal domain between the 
third and the fourth cysteines (Kluver et al. 2006, Krishnakumari et al. 2006). 
The C-terminal positively charged region in hBD-3 is packed against the 
internal domain, which contains two positive residues while the internal 
domain of hBD1 contains only one positive residue (Krishnakumari et al. 
2006). Moreover, the N-terminal helix in hBD-3 starts from Lys8, with residues 
1-7 being disordered (Conejo-Garcia et al. 2001). It has been previous showed 
that the C-terminal domain of hBD-3 and the internal domain of hBD-1 are 
fundamental for antimicrobial and chemotactic activity and also that the N-
terminal disordered domain of hBD-3 is not necessary for activity (Scudiero et 
al. 2010, Taylor et al. 2008). To verify these results we synthesized a novel 
molecule without the N-terminal domain of hBD-3 and with the internal 
domain of hBD-1, 3NI. Analog 3NI consists of the hBD-3 sequence plus the 
internal domain of hBD-1 and without the N-terminal domain of hBD-3. 
Furthermore, the C-terminal domain (8 amino acids) of hBD-3 has more 
positive charges (net charge: + 6) than the C-terminal domain (5 amino acids) 
of hBD-1 (net charge: + 2). The charged residues in the internal domain 
between the third and fourth cysteines residues also differ between hBD-3 
and hBD-1. In particular, hBD-3 has two glutamines and two lysines residues, 
whereas hBD-1 has only one lysine residue. Finally, hBD-3 has more net total 
positive charges (+ 11) than hBD-1 (+ 4) and the analogs all present a higher 
net positive charge compared to hBD-1 (3NI: +12; 3N: +11; 1C: +8). Moreover, 
it has been recently suggested that the antimicrobial activity of β-defensins is 
probably attributable to their reduced unstructured form (Scudiero et al. 
2010,  Schroeder et al. 2011). 
We tested analog 3NI and found that it exerts good antibacterial activity 
against E. coli, P. aeruginosa, E. faecalis at 2.5 µM and up to 100 mM NaCl, 
which confirms that the C-terminus of hBD3 and the internal domain of hBD-1 
are crucial for antibacterial activity and salt-resistance. (Krishnakumari et al. 
2006, Scudiero et al. 2010). The antiviral activity of the analog 3NI against HSV 
was similar to that of hBD-3 with a reduction of infectivity of 99% at 50 µM, 
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which is in accordance with previous studies of HIV (Conejo-Garcia et al. 2001, 
Weinberg et al. 2006, Cole et al. 2003).  
We used three epithelial cell lines (A549, CaCo-2 and Capan -1) derived from 
tissues normally expressing β defensins as a model to investigate the potential 
cytotoxic activity of our peptides. Interestingly, exposure of the cells to the 
wild type and chimeric peptides between 4 and 24 h did not result in a 
reduction of cell viability. Neither was the percentage of apoptotic cells 
affected by this treatment. Similarly, our analogs do not cause DNA damage, 
as demonstrated by the results of single-cell gel electrophoresis. After 48 h 
and within 72 h of exposure of the cells to the peptides, there was a small 
decrease in the percentage of cell proliferation (30%). These results coincide 
with the results of the apoptotic assay in which there was a minimal increase 
in the percentage of apoptotic cells (20%). In addition, we found, by confocal 
microscopy experiments, that the cells partially degrade the peptides 
between 24 and 72 h. We suggest that the reduction of cell proliferation 
within 72 h (30%) occurs via two mechanisms: a mild induction of apoptosis 
by peptides and digestion of peptides.  
It is also critical to note that the three cell lines showed different behaviour in 
proliferation and apoptotic tests: CaCo-2 cells were less susceptible to the 
effects of peptides than the other two cell lines. Moreover, proliferation and 
apoptotic tests revealed that Capan-1 cells were more sensitive than the 
other two cell lines to the effects exerted by the peptides. Additionally, our 
results obtained through confocal microscopy experiments, confirm that 
these peptides are not lethal for human epithelial cell lines. We also 
demonstrated that peptides are able to bind plasma membrane and be 
internalized into the cells by active mechanisms that involve early endosomes. 
However, we cannot exclude that other mechanisms participate to the 
internalization of defensins. Similarly, we suggest that cells are able to partial 
eliminate peptides within 18 h through lysosomes but we cannot exclude that 
others mechanisms participate to the removal of defensins from the cells. 
Finally, our results obtained from serum stability experiments demonstrated 
that hBD-3 is stable until 1 h of incubation in human serum and is degraded of 
about 45% in 24 h of incubation. Our results are partially in accordance with 
Antcheva et al. 2009 that reported a degradation rate of hBD-3 of around 20% 
just after 2 h.   
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      4 Conclusions and Perspectives 
 
The goal of the present work was to find defensin analogs with high 
antimicrobial activity without cell toxicity, giving the potential to these 
peptides to be exploited as therapeutic targets in infectious diseases. 
To this aim, we designed and synthesized a new defensin analog 3NI and 
characterized its antibacterial and antiviral activity. We found that 3NI possess 
a higher antimicrobial activity and a higher salt resistance compared to the 
wild type hBD-1 and hBD-3. Moreover, the results of cytotoxicity studies on 
three human epithelial cell lines of hBD-1, hBD-3, 1C, 3N and of 3NI analogs, 
supported by the confocal microscopy data, suggest that these peptides have 
a low effect on the reduction of cell viability (30% after 72 hours of incubation 
with cells), do not damage DNA and cause a minimum induction of apoptosis 
(20% after 72 hours of incubation with cells). Moreover, our experiments of 
stability in human serum demonstrated a good stability of hBD-3 (degradation 
of 45% after 2 hours).  
Altogether our results show that 1C, 3N the new molecule 3NI are 
characterized by a significant antimicrobial activity and salt resistance and 
they are not toxic for the three human epithelial cell lines tested.  
Our results allow us to candidate our analogs as potential therapeutic 
molecules to be tested in vivo. In addition, our results can be validated in vitro 
through experiments on co-culture of eukaryotic cells and bacteria. 
Then our results confirm the hypothesis that is possible to design new analogs 
with increased antimicrobial activity. In fact, an improved serum stability 
would be obtained designing analogs with a modified C-terminus or a cyclic 
structure; molecules with an increased antimicrobial activity would be 
achieved synthetizing smaller peptides and/or dimeric peptides.  
Moreover, since peptides are active against bacteria and viruses and do not 
exert relevant toxic effects on human cells, it would be of great interest to 
analyse directly “in vivo” the properties of wild type and analogs peptides in 
mice models of infectious diseases. It would possible to consider severe 
infections in several epithelia and organs due to pathogen viruses and 
bacteria. This approach will allow us to evaluate the most relevant 
pharmacological properties of peptides: drug efficacy (in physiological 
conditions and in condition of high salt concentrations), stability in serum, 
half-life and side effects.  
46 
 
Acknowledgments 
I want to thank Dott. Olga Scudiero for supporting the experimental design 
and for useful discussions.
47 
 
REFERENCES 
 
• Antcheva N, Morgera F, Creatti L, Vaccari L, Pag U, Pacor S, Shai Y, Sahl 
HG, Tossi A. Artificial beta-defensin based on a minimal defensin 
template. Biochem J. 2009;421(3):435-47. 
• Bals R. Epithelial antimicrobial peptides in host defense against 
infection. Respiratory Research 2000;1:141-50. 
• Bensch KW, Raida M, Mägert HJ, Schulz-Knappe P, Forssmann WG. 
hBD-1: a novel beta-defensin from human plasma. FEBS Lett. 
1995;368(2):331-5. 
• Brogden KA. Antimicrobial peptides: pore formers or metabolic 
inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238-50. 
• Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides 
important in innate immunity. FEBS J. 2011;278(20):3942-51.  
• Chandrababu KB, Ho B, Yang D. Structure, dynamics, and activity of an 
all-cysteine mutated human beta defensin-3 peptide analogue. 
Biochemistry 2009;48:6052-61. 
• Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, 
Voitenok NN. Neutrophil alpha-defensin human neutrophil peptide 
modulates cytokine production in human monocytes and adhesion 
molecule expression in endothelial cells. Eur Cytokine Netw. 
2000;11(2):257-66. 
• Cole AM, Lehrer RI. Minidefensins: antimicrobial peptides with activity 
against HIV-1. Current Pharmaceutical Design 2003;9:1463-73. 
• Conejo-Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jiménez J, 
Forsmann U, Andermann K, Klüuver E, Vogelmeier C, Becker D, 
Hedrich R, Forsmann W-G, Bals R. Identification of a novel, 
multifunctional ß-defensin (human ß-defensin 3) with specific 
antimicrobial activity. Cell Tissue Res. 2001;306:257-264. 
• Cunliffe RN. Alpha-defensins in the gastrointestinal tract. Mol 
Immunol. 2003;40(7):463-7. 
• Dance AM, Ralton L, Fuller Z, Milne L, Duthie S, Bestwick CS, Lin PK. 
Synthesis and biological activities of bisnaphthalimido polyamines 
derivatives: cytotoxicity, DNA binding, DNA damage and drug 
localization in breast cancer MCF 7 cells. Biochemical Pharmacology 
2005;69:19-27. 
• Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C, 
Granja J, Gritzen C, Weinberger D, Ghadiri MR, Parr TR, Jr. Systemic 
antibacterial activity of novel synthetic cyclic peptides. Antimicrobial 
Agents and Chemotherapy 2005;49:3302-10. 
48 
 
• Durr M, Peschel A. Chemokines meet defensins: the merging concepts 
of chemoattractants and antimicrobial peptides in host defense. 
Infection and Immunity 2002;70:6515-7. 
• Ferrari M, Fornasiero MC, Isetta AM. MTT colorimetric assay for 
testing macrophage cytotoxic activity in vitro. J Immunol Methods. 
1990;131(2):165-72. 
• Fujii G, Selsted M E, Eisenberg D. Defensins promote fusion and lysis of 
negatively charged membranes. Protein Sci. 1993;2:1301–1312. 
• Ganz T. Defensins in the urinary tract and other tissues. Journal of 
Infectious Diseases 2001;183 Suppl 1:S41-2. 
• Ganz T. Defensins: antimicrobial peptides of innate immunity. Nature 
Reviews. Immunology 2003;3:710-20. 
• Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, 
Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich 
R, Forssmann WG, Bals R. Identification of a novel, multifunctional 
beta-defensin (human beta-defensin 3) with specific antimicrobial 
activity. Its interaction with plasma membranes of Xenopus oocytes 
and the induction of macrophage chemoattraction. Cell and Tissue 
Research 2001;306:257-64. 
• Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson 
JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is 
inactivated in cystic fibrosis. Cell 1997;88:553-60. 
• Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic 
from human skin. Nature 1997;387:861. 
• Harder J, Bartels J, Christophers E, Schroder JM. Isolation and 
characterization of human beta -defensin-3, a novel human inducible 
peptide antibiotic. J Biol Chem. 2001;276(8):5707-13. 
• Hazlett L, Wu M. Defensins in innate immunity. Cell and Tissue 
Research 2010;343:175-88. 
• Hoover DM, Chertov O, Lubkowski J. The structure of human beta-
defensin-1: new insights into structural properties of beta-defensins. 
Journal of Biological Chemistry 2001;276:39021-6. 
• Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. Antimicrobial 
characterization of human beta-defensin 3 derivatives. Antimicrobial 
Agents and Chemotherapy 2003;47:2804-9. 
• Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate 
immune system. Science 2010;327:291-5. 
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev 
Immunol. 2002;20:197-216.  
• Jung S, Mysliwy J, Spudy B, Lorenzen I, Reiss K, Gelhaus C, Podschun R, 
Leippe M, Grotzinger J. Human beta-defensin 2 and beta-defensin 3 
chimeric peptides reveal the structural basis of the pathogen 
49 
 
specificity of their parent molecules. Antimicrobial Agents and 
Chemotherapy 2011;55:954-60. 
• King AE, Fleming DC, Critchley HO, Kelly RW. Regulation of natural 
antibiotic expression by inflammatory mediators and mimics of 
infection in human endometrial epithelial cells. Mol Hum Reprod. 
2002;8(4):341-9. 
• King AE, Fleming DC, Critchley HO, Kelly RW. Differential expression of 
the natural antimicrobials, beta-defensins 3 and 4, in human 
endometrium. Journal of Reproductive Immunology 2003;59:1-16. 
• Kluver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, 
Adermann K. Structure-activity relation of human beta-defensin 3: 
influence of disulfide bonds and cysteine substitution on antimicrobial 
activity and cytotoxicity. Biochemistry 2005;44:9804-16. 
• Kluver E, Adermann K, Schulz A. Synthesis and structure-activity 
relationship of beta-defensins, multi-functional peptides of the 
immune system. Journal of Peptide Science 2006;12:243-57. 
• Krishnakumari V, Singh S, Nagaraj R. Antibacterial activities of 
synthetic peptides corresponding to the carboxy-terminal region of 
human beta-defensins 1-3. Peptides 2006;27:2607-13. 
• Krishnakumari V, Rangaraj N, Nagaraj R. Antifungal activities of human 
beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to 
Phd3. Antimicrobial Agents and Chemotherapy 2009;53:256-60. 
• Lehrer RI. Primate defensins. Nature Reviews. Microbiology 
2004;2:727-38. 
• Lehrer RI. Immunology: Peptide gets in shape for self-defence. Nature 
2011;469:309-10. 
• Lichtenstein, A. Mechanism of mammalian cell lysis mediated by 
peptide defensins. Evidence for an initial alteration of the plasma 
membrane. J. Clin. Invest. 1991;88:93–100.  
• Maisetta G, Batoni G, Esin S, Florio W, Bottai D, Favilli F, Campa M. In 
vitro bactericidal activity of human beta-defensin 3 against multidrug-
resistant nosocomial strains. Antimicrobial Agents and Chemotherapy 
2006;50:806-9. 
• McKelvey-Martin VJ, Ho ET, McKeown SR, Johnston SR, McCarthy PJ, 
Rajab NF, Downes CS. Emerging applications of the single cell gel 
electrophoresis (Comet) assay. I. Management of invasive transitional 
cell human bladder carcinoma. II. Fluorescent in situ hybridization 
Comets for the identification of damaged and repaired DNA sequences 
in individual cells. Mutagenesis 1998;13:1-8. 
• Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive 
immune response. Curr Opin Immunol. 1997;9(1):4-9. 
50 
 
• Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 
2000;343(5):338-44. 
• Medzhitov R. Innate immunity: quo vadis? Nat Immunol. 
2010;11(7):551-3. 
• Patil A, Hughes AL, Zhang G. Rapid evolution and diversification of 
mammalian alpha-defensins as revealed by comparative analysis of 
rodent and primate genes. Physiol Genomics. 2004;20(1):1-11. 
• Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-
defensins. Cellular and Molecular Life Sciences 2006;63:1294-313. 
• Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and 
promises. International Journal of Antimicrobial Agents 2004;24:536-
47. 
• Sahl HG, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A. Mammalian 
defensins: structures and mechanism of antibiotic activity. Journal of 
Leukocyte Biology 2005;77:466-75. 
• Sass V, Schneider T, Wilmes M, Korner C, Tossi A, Novikova N, 
Shamova O, Sahl HG. Human beta-defensin 3 inhibits cell wall 
biosynthesis in Staphylococci. Infection and Immunity. 2010;78:2793-
800. 
• Schneider JJ, Unholzer A, Schaller M, Schäfer-Korting M, Korting HC. 
Human defensins. J Mol Med (Berl). 2005;83(8):587-95.  
• Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, 
Buchner J, Schaller M, Stange EF, Wehkamp J. Reduction of disulphide 
bonds unmasks potent antimicrobial activity of human beta-defensin 
1. Nature 469:419-23. 
• Scudiero O, Galdiero S, Cantisani M, Di Noto R, Vitiello M, Galdiero M, 
Naclerio G, Cassiman JJ, Pedone C, Castaldo G, Salvatore F. Novel 
synthetic, salt-resistant analogs of human beta-defensins 1 and 3 
endowed with enhanced antimicrobial activity. Antimicrobial Agents 
and Chemotherapy 2010;54:2312-22. 
• Selsted ME. Theta-defensins: cyclic antimicrobial peptides produced by 
binary ligation of truncated alpha-defensins. Curr Protein Pept Sci. 
2004;5(5):365-71. 
• Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial 
immune response. Nat Immunol. 2005;6(6):551-7. 
• Speit G, Schutz P, Bonzheim I, Trenz K, Hoffmann H. Sensitivity of the 
FPG protein towards alkylation damage in the comet assay. Toxicology 
Letters 2004;146:151-8. 
• Taylor K, McCullough B, Clarke DJ, Langley RJ, Pechenick T, Hill A, 
Campopiano DJ, Barran PE, Dorin JR, Govan JR. Covalent dimer species 
of beta-defensin Defr1 display potent antimicrobial activity against 
51 
 
multidrug-resistant bacterial pathogens. Antimicrobial Agents and 
Chemotherapy 2007;51:1719-24. 
• Taylor K, Clarke DJ, McCullough B, Chin W, Seo E, Yang D, Oppenheim 
J, Uhrin D, Govan JR, Campopiano DJ, MacMillan D, Barran P, Dorin JR. 
Analysis and separation of residues important for the chemoattractant 
and antimicrobial activities of beta-defensin 3. Journal of Biological 
Chemistry 2008;283:6631-9. 
• Vankeerberghen A, Scudiero O, De Boeck K, Macek M Jr, Pignatti PF, 
Van Hul N, Nuytten H, Salvatore F, Castaldo G, Zemkova D, Vavrova V, 
Cassiman JJ, Cuppens H. Distribution of human beta-defensin 
polymorphisms in various control and cystic fibrosis populations. 
Genomics. 2005;85(5):574-81. 
• Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr., Ganz T. Human 
beta-defensin-1: an antimicrobial peptide of urogenital tissues. Journal 
of Clinical Investigation 1998;101:1633-42. 
• Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, 
Schwind B, Duchrow M, Wohlschlager C, Feller AC, Stange EF. Human 
beta-defensin 2 but not beta-defensin 1 is expressed preferentially in 
colonic mucosa of inflammatory bowel disease. European Journal of 
Gastroenterology and Hepatology 2002;14:745-52. 
• Weinberg A, Quinones-Mateu ME, Lederman MM. Role of human 
beta-defensins in HIV infection. Advances in Dental Research 
2006;19:42-8. 
• Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the 
human immune system. Virulence 2010;1:440-64. 
• Wimley W C, Selsted M E, White S H. Interactions between human 
defensins and lipid bilayers: evidence for formation of multimeric 
pores. Protein Sci. 1994;3:1362–1373. 
• Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, 
Lubkowski J, Lu W. Engineering disulfide bridges to dissect 
antimicrobial and chemotactic activities of human beta-defensin 3. 
Proceedings of the National Academy of Sciences of the United States 
of America 2003;100:8880-5. 
• Yanagi S, Ashitani J, Ishimoto H, Date Y, Mukae H, Chino N, Nakazato 
M. Isolation of human beta-defensin-4 in lung tissue and its increase in 
lower respiratory tract infection. Respir Res. 2005;6:130. 
• Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, 
Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ. 
Beta-defensins: linking innate and adaptive immunity through 
dendritic and T cell CCR6. Science 1999;286:525-8. 
